openPR Logo
Press release

Chronic Hepatitis B Virus Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight

06-26-2025 07:54 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Chronic Hepatitis B Virus Clinical Trials

Chronic Hepatitis B Virus Clinical Trials

(Albany, USA) DelveInsight's, "Chronic Hepatitis B Virus Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Chronic Hepatitis B Virus pipeline landscape. It covers the Chronic Hepatitis B Virus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Chronic Hepatitis B Virus Pipeline. Dive into DelveInsight's comprehensive report today! @ Chronic Hepatitis B Virus Pipeline Outlook - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Chronic Hepatitis B Virus Pipeline Report
• In April 2025, Vir Biotechnology Inc. announced a phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.
• In April 2025, GlaxoSmithKline announced a study will assess the safety, efficacy and immune response following the sequential treatment of GlaxoSmithKline's (GSK) ASO compound (GSK3228836) and CHB-TI (GSK3528869A) in participants 18 to 65 years stable on NA treatment for CHB. The aim is to quantify the efficacy of sequential therapy as well as to determine an added value of sequential therapy over GSK3228836 therapy in CHB patients treated with NAs. In addition, the study will assess the effect of different treatment durations of GSK3228836 (12 or 24 weeks) prior to initiating GSK3528869A treatment.
• DelveInsight's Chronic Hepatitis B Virus pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Chronic Hepatitis B Virus treatment.
• The leading Chronic Hepatitis B Virus Companies such as Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm. And others.
• Promising Chronic Hepatitis B Virus Pipeline Therapies such as Peginterferon Alfacon, Daplusiran/Tomligisiran Dose Level 1, Bepirovirsen, Tenofovir disoproxil fumarate (TDF), VIR-2218, PEG-IFNα, and others.

Stay ahead with the most recent pipeline outlook for Chronic Hepatitis B Virus. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Chronic Hepatitis B Virus Treatment Drugs - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Hepatitis B Virus Emerging Drugs Profile
Pradefovir: Ligand Pharmaceuticals
Pradefovir is an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of hepatitis B virus (HBV) infection. The drug is developing using Ligand's HepDirect technology. Currently the product is in Phase III stage of development for the treatment of Chronic Hepatitis B.

RG6346: Dicerna Pharmaceuticals
RG6346 is an investigational GalXCTM RNAi therapeutic candidate in development in collaboration with Roche for the treatment of chronic HBV infection. RG6346 is designed to employ RNA interference to selectively knock down specific genes involved in the creation of HBV messenger RNA (mRNA) and the entry of the virus into liver cells. Preclinical data have demonstrated greater than 99.9% reduction in circulating HBsAg, as observed in mouse models of HBV infection. Unlike current therapies that typically provide long-term suppression of the virus, RG6346 has the potential to provide a functional cure for patients living with chronic HBV. Dicerna is currently conducting a Phase II trial of RG6346 in adult patients with chronic HBV infection.

The Chronic Hepatitis B Virus Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Hepatitis B Virus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Hepatitis B Virus Treatment.
• Chronic Hepatitis B Virus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Hepatitis B Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Hepatitis B Virus market

Explore groundbreaking therapies and clinical trials in the Chronic Hepatitis B Virus Pipeline. Access DelveInsight's detailed report now! @ New Chronic Hepatitis B Virus Drugs - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Hepatitis B Virus Companies
Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm and others.

Chronic Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Chronic Hepatitis B Virus Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Unveil the future of Chronic Hepatitis B Virus Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Hepatitis B Virus Market Drivers and Barriers - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Chronic Hepatitis B Virus Pipeline Report
• Coverage- Global
• Chronic Hepatitis B Virus Companies- Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm. And others.
• Chronic Hepatitis B Virus Pipeline Therapies- Peginterferon Alfacon, Daplusiran/Tomligisiran Dose Level 1, Bepirovirsen, Tenofovir disoproxil fumarate (TDF), VIR-2218, PEG-IFNα, and others.
• Chronic Hepatitis B Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Hepatitis B Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Chronic Hepatitis B Virus Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Hepatitis B Virus Companies, Key Products and Unmet Needs - https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
• Introduction
• Executive Summary
• Chronic Hepatitis B Virus Infection: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Chronic Hepatitis B Virus Infection - DelveInsight's Analytical Perspective
• Late Stage Products (Phase III)
• Pradefovir: Ligand Pharmaceuticals
• Drug profiles in the detailed report.....
• Mid Stage Products (Phase II)
• RG6346: Dicerna Pharmaceuticals
• Drug profiles in the detailed report.....
• Early Stage Products (Phase I/II)
• Drug name: Company name
• Drug profiles in the detailed report.....
• Early Stage Products (Phase I)
• VIR-3434: Vir Biotechnology
• Drug profiles in the detailed report.....
• Preclinical Stage Products
• SBT8230: Silverback Therapeutics
• Drug profiles in the detailed report.....
• Inactive Products
• Chronic Hepatitis B Virus Infection Key Companies
• Chronic Hepatitis B Virus Infection Key Products
• Chronic Hepatitis B Virus Infection - Unmet Needs
• Chronic Hepatitis B Virus Infection - Market Drivers and Barriers
• Chronic Hepatitis B Virus Infection - Future Perspectives and Conclusion
• Chronic Hepatitis B Virus Infection Analyst Views
• Chronic Hepatitis B Virus Infection Key Companies
• Appendix

Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/ats-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Hepatitis B Virus Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight here

News-ID: 4083994 • Views:

More Releases from DelveInsight Business Research

KRAS Inhibitors Market Insight 2034: Revenue, Statistics, EMA, PDMA, FDA Approvals, Medication, Clinical Trials, Therapies, Prevalence, Companies by DelveInsight
KRAS Inhibitors Market Insight 2034: Revenue, Statistics, EMA, PDMA, FDA Approva …
(Albany, USA) The report titled "KRAS Inhibitors Market Insights, Epidemiology, and Market Forecast- 2034" by DelveInsight provides a comprehensive analysis of KRAS Inhibitors. It presents a detailed overview of the historical and projected epidemiological data, along with the market trends for KRAS Inhibitors in the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report on the KRAS Inhibitors market offers up-to-date treatment methods,
Psoriasis Pipeline Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight
Psoriasis Pipeline Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, The …
(Albany, United States) "Psoriasis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Psoriasis Market. As per DelveInsight's assessment, globally, Psoriasis pipeline constitutes 80+ key companies continuously working towards developing 80+ Psoriasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Psoriasis Pipeline report embraces in-depth commercial and clinical assessment of
Multiple Sclerosis Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight
Multiple Sclerosis Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clin …
(Albany, USA) DelveInsight's 'Multiple Sclerosis Competitive Landscape 2025' report provides comprehensive global coverage of pipeline multiple sclerosis medication in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the multiple sclerosis pipeline domain. Key Takeaways from the Multiple Sclerosis Pipeline Report • DelveInsight's multiple sclerosis competitive report depicts a robust space with 60+ active players working to develop 75+ pipeline multiple sclerosis
Chronic Pruritus Market Analysis 2034: Statistics, Revenue, Clinical Trials, Prevalence, Medication, FDA, EMA, PDMA Approvals, and Companies by DelveInsight
Chronic Pruritus Market Analysis 2034: Statistics, Revenue, Clinical Trials, Pre …
(Albany, USA) DelveInsight's "Chronic Pruritus - Market Insight, Epidemiology, And Market Forecast - 2034′′ report offers an in-depth understanding of the Chronic Pruritus, historical and forecasted epidemiology as well as the Chronic Pruritus market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The Chronic Pruritus Market is making significant strides, fueled by innovative treatment approaches and ongoing research advancements. DelveInsight's latest 7MM report

All 5 Releases


More Releases for Vir

Investigation for NASDAQ: VIR Investors over possible Wrongdoing at Vir Biotechn …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Vir Biotechnology, Inc. Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Vir Biotechnology directors breached their fiduciary duties and caused damage to the company and its shareholders. San Francisco, CA based
SOFTWARE-DEFINED NETWORKING AND NETWORK FUTUALIZATION MARKET knowNCTION VIR indu …
“The SDN and NFV is picking up noticeable quality because of the developing mechanical progressions in systems administration and server farm union. SDN is a momentous systems administration design, which is ready to totally alter the current systems administration and server farm foundation. The SDN building structure is set to reclassify the systems administration framework to meet the developing number of system clients devouring a high data transfer capacity. With
Investigation announced for Investors in shares of Vir Biotechnology, Inc. (NASD …
Vir Biotechnology, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Vir Biotechnology, Inc. regarding its business, its prospects and its operations were materially false
Balancing Valves Market 2017- IMI Hydronic, Danfoss, Frese A/S, Caleffi, VIR Gro …
Apex Market Reports, recently published a detailed market research study focused on the "Balancing Valves Market" across the global, regional and country level. The report provides 360° analysis of "Balancing Valves Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Balancing Valves industry, and estimates the future trend of Balancing Valves market
Global Manual Balancing Valves Market 2017 : IMI Hydronic, Danfoss, Frese A/S, C …
QY Market Research published, Top Manufacturers Analysis Of Bidets Research Report. A market study based on the "Manual Balancing Valves Market" across the globe, recently added to the repository of Market Research, is titled ‘Global Manual Balancing Valves Market 2017’. The research report analyses the historical as well as present performance of the worldwide Manual Balancing Valves industry, and makes predictions on the future status of Manual Balancing Valves market
Global Automatic Balancing Valves Market Forecast 2017 - 2022 - IMI Hydronic , D …
According to Automatic Balancing Valves Market Report by Market.Biz: China Automatic Balancing Valves market sales revenue and India Automatic Balancing Valves market sales revenue is expected to register CAGRs of XX.XX % and XX.XX% respectively over the forecast period. Automatic Balancing Valves consumption in the ASEAN region's growth rate of XX.XX% outperforming many countries in the Europe and Americas on